Search results for "LPI"

showing 10 items of 535 documents

Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.

2005

Amisulpride is a clinically effective antipsychotic drug in a broad dose range with low propensity for extrapyramidal symptoms (EPS). Daily doses and plasma levels of amisulpride were analyzed within a large-scale therapeutic drug monitoring (TDM) survey to find plasma level ranges for optimized treatment under naturalistic conditions. Data of 378 schizophrenic patients treated with amisulpride (100-1550 mg) were included (40% female). Amisulpride plasma levels were analyzed at steady state; assessment comprised improvement (CGI-I) and side-effects, particularly EPS. For detection of cut-off values regarding non-response or EPS, receiver operating characteristics (ROC) curves were applied a…

AdultMalemedicine.medical_specialtyDyskinesia Drug-InducedAdolescentmedicine.drug_classStatistics as TopicAtypical antipsychoticPharmacologyGastroenterologyExtrapyramidal symptomsInternal medicineGermanymedicineHumansAmisulprideBiological PsychiatryAgedRetrospective StudiesAged 80 and overNeurologic ExaminationPsychiatric Status Rating ScalesReceiver operating characteristicmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryDopamine antagonistMiddle Agedmedicine.diseasePsychiatry and Mental healthDose–response relationshipROC CurveSchizophreniaTherapeutic drug monitoringSchizophreniaFemalemedicine.symptomAmisulprideDrug MonitoringSulpiridebusinessmedicine.drugAntipsychotic AgentsJournal of psychiatric research
researchProduct

Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.

2007

Aims Anderson–Fabry disease (AFD) is an uncommon X-linked disorder caused by deficient activity of the lysosomal enzyme α-galactosidase A. The Fabry Outcome Survey is a European database designed to monitor the long-term efficacy and safety of enzyme replacement therapy (ERT) with agalsidase alfa. The aim of this study was to determine the prevalence and characteristics of cardiac disease in AFD patients. Methods and results Clinical and laboratory data were available in 714 patients from 11 countries (mean age 35 ± 17 years, 369 women, 336 treated). The prevalence of angina was 23 vs. 22%; palpitations and arrhythmias 27 vs. 26%; exertional dyspnoea 23 vs. 23%; and syncope 2 vs. 4%, in wom…

AdultMalemedicine.medical_specialtyHeart diseaseHeart DiseasesCardiomyopathyLeft ventricular hypertrophySyncopeAnginaRisk FactorsInternal medicinemedicinePalpitationsPrevalenceHumansVascular diseasebusiness.industryEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseaseRecombinant ProteinsSurgeryEuropeIsoenzymesDyspneaTreatment OutcomeEchocardiographyalpha-GalactosidaseFabry DiseaseFemaleHypertrophy Left Ventricularmedicine.symptomCardiology and Cardiovascular MedicinebusinessGlomerular Filtration RateEuropean heart journal
researchProduct

Odontogenic Infections: A 1-year Retrospective Study.

2015

ABSTRACT Objectives The purpose of this study was to analyze the prevalence, demographic patterns and management of odontogenic infections in patients undergoing treatment in an outpatient dental emergency service of a university hospital. Materials and methods In a retrospective study of the year 2012, all patients suffering from odontogenic infections were included. Demographic data, diagnosis and the conducted treatment were analyzed. Odontogenic infections were defined as pulpitis, apical and marginal periodontitis, abscesses and pericoronitis. Results A total of 2,058 out of 4,209 emergency patients suffered from odontogenic infections. The majority (45.0%) had an apical periodontitis,…

AdultMalemedicine.medical_specialtyPericoronitisAdolescentDental emergencyYoung AdultInternal medicineGermanyPrevalenceMedicineHumansPulpitisClinical significanceAbscessChildPeriodontitisGeneral DentistryPeriodontal DiseasesAgedRetrospective StudiesPeriodontitisAged 80 and overbusiness.industryAmoxicillinInfantPulpitisRetrospective cohort studyBacterial InfectionsAmoxicillinMiddle Agedmedicine.diseaseAbscessAnti-Bacterial AgentsTooth DiseasesChild PreschoolFemalePericoronitismedicine.symptombusinessPeriapical Periodontitismedicine.drugThe journal of contemporary dental practice
researchProduct

Treatment of chronic depression with sulpiride: evidence of efficacy in placebo-controlled single case studies

1994

Systematic variation of treatment (alternating active drug and placebo in four treatment periods) in individual patients is proposed to collect preliminary evidence for a therapeutic effect of sulpiride in chronic depression; the ARIMA model is applied to evaluate the intervention effects of the tentatively effective treatment in single subjects. Ten single cases of chronic depression with a diagnosis of major depression or dysthymia were selected and seven of these provided evidence for beneficial effects of sulpiride with regard to treating the symptoms of depression and anxiety. However, the drug effects were intraindividually not always replicable. The results obtained with these single…

AdultMalemedicine.medical_specialtyPlacebo-controlled studyAnxietyPlaceboDouble-Blind MethodInternal medicinemedicineHumansPsychiatryDepression (differential diagnoses)Psychiatric Status Rating ScalesPharmacologyDepressive DisorderCross-Over StudiesTherapeutic effectCrossover studyClinical trialCase-Control StudiesChronic DiseaseAnxietyFemaleSulpiridemedicine.symptomPsychologySulpiridemedicine.drugPsychopharmacology
researchProduct

Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder.

2008

Abstract Because of a unique pharmacodynamic profile, amisulpride seems appropriate for treatment of elderly patients with schizophrenia. In a large-scale naturalistic therapeutic drug monitoring study, daily amisulpride dose, trough and dose-corrected amisulpride plasma levels, co-medication, clinical effectiveness (CGI) and side effects (UKU) were compared between age groups in 395 patients with schizophrenia or schizoaffective disorder (46% women; mean age 39.1 ± 14.2 years, range 18–83 years) under amisulpride therapy. Mean amisulpride doses (574 ± 269 mg/day), plasma levels (304 ± 274 ng/mL), dose-corrected amisulpride plasma levels (C/D ratios, 0.52 ± 0.41 ng/mL:mg), clinical respons…

AdultMalemedicine.medical_specialtySide effectAdolescentmedicine.drug_classPoison controlAtypical antipsychoticSchizoaffective disorderComorbidityGastroenterologyYoung AdultExtrapyramidal symptomsInternal medicinemedicineHumansPharmacology (medical)AmisulpridePsychiatryAgedPharmacologyAged 80 and overDose-Response Relationship DrugDopamine antagonistAge FactorsMiddle Agedmedicine.diseasePsychiatry and Mental healthPsychotic DisordersSchizophreniaSchizophreniaFemalemedicine.symptomAmisulprideDrug MonitoringSulpiridePsychologymedicine.drugAntipsychotic AgentsJournal of psychopharmacology (Oxford, England)
researchProduct

Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.

2006

INTRODUCTION: It is assumed that female and male schizophrenic patients respond differentially to acute and chronic treatment with antipsychotics because of pharmacokinetic and pharmacodynamic factors linked to hormonal and constitutional gender differences. However, to date no empirical evidence exists in support of this notion. METHODS: In a naturalistic clinical study, we investigated gender differences in a sample of schizophrenic inpatients with acute exacerbation treated with the atypical antipsychotic amisulpride, a selective dopamine D2/D3 receptor antagonist with proven antipsychotic efficacy. Prescribed amisulpride dose, plasma level, clinical response (CGI), and side effects (UKU…

AdultMalemedicine.medical_specialtySide effectExacerbationmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticPharmacologyDrug Administration ScheduleSex FactorsInternal medicinemedicineHumansPharmacology (medical)AmisulprideAntipsychoticmedicine.diagnostic_testGeneral MedicineDrug ToleranceHospitalizationPsychiatry and Mental healthTherapeutic drug monitoringPharmacodynamicsSchizophreniaFemaleAmisulprideDrug MonitoringSulpiridePsychologySulpiridemedicine.drugAntipsychotic AgentsPharmacopsychiatry
researchProduct

Long-Term Effects of the Substituted Benzamide Derivative Amisulpride on Baseline and Stimulated Prolactin Levels

2002

In the present study, we investigated the long-term effects of treatment with amisulpride, a substituted benzamide derivative, as compared with the effects of treatment with flupenthixol, a thioxanthene, on the prolactin levels in schizophrenic patients. After completing 6 weeks of medication with either amisulpride or flupenthixol, the patients entered a long-term maintenance treatment with amisulpride 200–600 mg/day or flupenthixol 5–15 mg/day for a maximum of 12 months with a subsequent drug-free follow-up until month 15. Eighteen initially included patients were still participating in the study at month 6. In the flupenthixol group, only 1 patient treated reached month 12, and none of t…

AdultMalemedicine.medical_specialtyTime FactorsThyrotropin-releasing hormoneFlupenthixolDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicinemedicineHumansAmisulprideBenzamideThyrotropin-Releasing HormoneBiological PsychiatryMiddle AgedProlactinProlactinFlupentixolFlupenthixolPsychiatry and Mental healthNeuropsychology and Physiological PsychologyEndocrinologychemistrySchizophreniaFemaleAmisulprideSulpiridePsychologyAntipsychotic Agentsmedicine.drugHormoneNeuropsychobiology
researchProduct

The Western Alps from the Jurassic to Oligocene: spatio-temporal constraints and evolutionary reconstructions

2005

Abstract Despite extensive research in the last 150 years, the regional tectonic reconstruction of the Western Alps has remained controversial. The curved orogenic belt consists of several ribbon-like continental terranes (Sesia/Austroalpine, Internal Crystalline Massifs, Brianconnais), which are separated by two or more ophiolitic sutures (Piemonte, Valais, Antrona?, Lanzo/Canavese?). High-pressure (HP) metamorphism of each terrane occurred during distinct orogenic episodes: at ∼65 Ma in the Sesia/Austroalpine, at ∼45 Ma in the Piemonte zone and at ∼35 Ma in the Internal Crystalline Massifs. It is suggested that these events reflect individual accretionary episodes, which together with kin…

African PlatePaleontologyAccretionary wedgeSubductionValais OceanOceanic crustAlpine orogenyGeneral Earth and Planetary SciencesMetamorphismGeomorphologyGeologyTerraneEarth-Science Reviews
researchProduct

Dopaminergic modulation of low-Mg2+-induced epileptiform activity in the intact hippocampus of the newborn mouse in vitro

2012

To investigate whether epileptiform activity in the immature brain is modulated by dopamine, we examined the effects of dopaminergic agonists and antagonists in an intact in vitro preparation of the isolated corticohippocampal formation of immature (postnatal days 3 and 4) C57/Bl6 mice using field potential recordings from CA3. Epileptiform discharges were induced by a reduction of the extracellular Mg(2+) concentration to 0.2 mM. These experiments revealed that low concentrations of dopamine ( 3 μM dopamine enhanced epileptiform activity. The D1-agonist SKF38393 (10 μM) had a strong proconvulsive effect, and the D2-like agonist quinpirole (10 μM) mediated a weak anticonvulsive effect. The …

AgonistChemistrymedicine.drug_classAntagonistPharmacologyReceptor antagonistCellular and Molecular NeuroscienceQuinpiroleDopamine receptorDopamine receptor D3DopaminemedicineSulpiridemedicine.drugJournal of Neuroscience Research
researchProduct

Actions of two GABAA receptor benzodiazepine-site ligands that are mediated via non-γ2-dependent modulation.

2011

The potent sedative-hypnotic zolpidem and the convulsant methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate (DMCM) act primarily by binding to the benzodiazepine site of the main inhibitory neurotransmitter receptor, the pentameric γ-aminobutyric acid type A receptor (GABA(A)). This binding depends critically on the wild-type F77 residue of the GABA(A) receptor γ2 subunit. Mice with γ2 subunit F77I point mutation (γ2I77 mouse line) lose the high-affinity nanomolar binding of these ligands as well as their most robust behavioral actions at low doses. Interestingly, the γ2I77 mice offer a tool to study the actions of these substances mediated via other possible binding sites of the GABA(A…

AgonistMaleZolpidemAzidesmedicine.drug_classPyridinesConvulsantsPharmacologyLigandsGABAA-rho receptor03 medical and health scienceschemistry.chemical_compoundBenzodiazepinesMice0302 clinical medicineDMCMmedicineAnimalsHumansHypnotics and SedativesBinding site030304 developmental biologyPharmacology0303 health sciencesBenzodiazepineBinding SitesBehavior AnimalGABAA receptorBrainLigand (biochemistry)Receptors GABA-AMice Inbred C57BLZolpidemProtein SubunitsHEK293 CellschemistryAutoradiographyFemale030217 neurology & neurosurgerymedicine.drugCarbolinesProtein BindingEuropean journal of pharmacology
researchProduct